Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 11/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4193428 | 0.91 | FAAH (0.43) | FAAHCNR1 | |
| SCHEMBL4193435 | 0.91 | FAAH (0.43) | FAAHCNR1 | |
| SCHEMBL4088458 | 0.85 | CNR1 (0.47) | FAAHCNR1CNR2CYP2C19KCNH2 | |
| SCHEMBL4078364 | 0.82 | CNR1 (0.55) | FAAHCNR1 | |
| SCHEMBL9596858 | 0.81 | EPHX2 (0.48) | — | |
| SCHEMBL4084883 | 0.81 | HPGD (0.43) | FAAHCNR1MGLL | |
| SCHEMBL4635589 | 0.81 | FAAH (0.48) | FAAHCNR1CNR2 | |
| SCHEMBL4635584 | 0.81 | FAAH (0.48) | FAAHCNR1CNR2 | |
| SCHEMBL4635988 | 0.80 | ALDH1A1 (0.41) | FAAHCYP2C19MGLL | |
| SCHEMBL4079987 | 0.79 | CNR1 (0.57) | FAAHCNR1CNR2CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1617839-B1 | THE USE OF AZETIDINECARBOXAMIDE DERIVATIVES IN THERAPY | VERNALIS RES LTD (GB) | 2008-06-18 | — | — | EP | claimed |
| US-20060276452-A1 | Use of azetidinecarboxamide derivatives in therapy | VERNALIS RESEARCH LIMITED (GB) | 2006-12-07 | — | — | US | claimed |
| EP-1617839-A1 | THE USE OF AZETIDINECARBOXAMIDE DERIVATIVES IN THERAPY | VERNALIS RESEARCH LIMITED (GB) | 2006-01-25 | — | — | EP | claimed |
| WO-2004096209-A1 | THE USE OF AZETIDINECARBOXAMIDE DERIVATIVES IN THERAPY | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | claimed |
| EP-1049672-B1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RES LTD (GB) | 2003-09-17 | — | — | EP | claimed |
| EP-1212054-A2 | AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES | VERNALIS RESEARCH LIMITED (GB) | 2002-06-12 | — | — | EP | claimed |
| US-6403574-B1 | TRANQUILIZERS, ANTIEPILEPTIC, MUSCLE RELAXATION PRIOR TO SURGERY | VERNALIS RESEARCH LIMITED (GB) | 2002-06-11 | — | — | US | claimed |
| WO-2001007023-A2 | AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES | VERNALIS RESEARCH LIMITED (GB) | 2001-02-01 | — | — | WO | claimed |
| EP-1049672-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2000-11-08 | — | — | EP | claimed |
| WO-1999037612-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 1999-07-29 | — | — | WO | claimed |
| EP-1617839-B1 | THE USE OF AZETIDINECARBOXAMIDE DERIVATIVES IN THERAPY | VERNALIS RES LTD (GB) | 2008-06-18 | — | — | EP | disclosed |
| US-20060276452-A1 | Use of azetidinecarboxamide derivatives in therapy | VERNALIS RESEARCH LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| EP-1617839-A1 | THE USE OF AZETIDINECARBOXAMIDE DERIVATIVES IN THERAPY | VERNALIS RESEARCH LIMITED (GB) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004096209-A1 | THE USE OF AZETIDINECARBOXAMIDE DERIVATIVES IN THERAPY | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| EP-1049672-B1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RES LTD (GB) | 2003-09-17 | — | — | EP | disclosed |
| EP-1212054-A2 | AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES | VERNALIS RESEARCH LIMITED (GB) | 2002-06-12 | — | — | EP | disclosed |
| US-6403574-B1 | TRANQUILIZERS, ANTIEPILEPTIC, MUSCLE RELAXATION PRIOR TO SURGERY | VERNALIS RESEARCH LIMITED (GB) | 2002-06-11 | — | — | US | disclosed |
| WO-2001007023-A2 | AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES | VERNALIS RESEARCH LIMITED (GB) | 2001-02-01 | — | — | WO | disclosed |
| EP-1049672-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037612-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276452-A1 | Use of azetidinecarboxamide derivatives in therapy | CNR1, CNR2, GPR18 | FAAH 5/4885CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.